4 Week, Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease

• Status: Completed
• Trial end date: 2010-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary purpose of the study is to determine the safety and tolerability of AZD1446 vs Placebo given as an add-on treatment to Donepezil for 4 weeks in patients with mild to moderate Alzheimer's disease.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Donepezil

Criteria

Inclusion Criteria:

• history of progressive worsening of memory and other cognitive functions for at least 12 months

• treatment with stable dose of donepezil (10 mg) for at least 3 months

• the patient should have an appropriate caregiver, who is required for all study visits

Exclusion Criteria:

• history of allergy/hypersensitivity reactions

• significant neurological disease or dementia other than Alzheimer's disease

• myocardial infarction or acute coronary syndrome within the last year